Amrinone (Lactate)

Amrinone (Lactate) is a vasodilator with positive inotropic properties, belongs to phosphodisterase inhibitors. Amrinone (Lactate) is used for the short term management of heart failure unresponsive to other forms of therapy. The mechanism of action has not been fully determined , however it appears to involve an increase in cAMP concentration due to inhibition of phosphodisterase leading to an increased contractile force in cardiac muscle. Amrinone (Lactate) is given by intravenous route.

Brands
Adult Dose
Dose: 5 to 10 mcg per kg of body weight per minute
Single Dose: 7.5 (7.5)
Frequency: As recommended.
Route: IV
Instructions: Ths is maintanance dose. the dose should be adjusted according to clinical response. Up to 10 mg (base) per kg of body weight per day, although some patients have been given doses up to 18 mg per kg per day for short durations.
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin. . The Molecular Weight of Amrinone (Lactate) is 277.30.
Contraindications
Amrinone (Lactate) is contraindicated in conditions like Hypersensitivity to the drug.
Effects
The severe or irreversible adverse effects of Amrinone (Lactate), which give rise to further complications include Cardiac arrhythmias, Hypotension, Hepatosplenomegaly, Hepatosplenomegaly.The signs and symptoms that are produced after the acute overdosage of Amrinone (Lactate) include Thrombocytopenia.The symptomatic adverse reactions produced by Amrinone (Lactate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Fever, Local pain, Hypersensitivity reactions, Chest pain, GI disturbance, Nail discoloration.
Indications
Amrinone (Lactate) is primarily indicated in conditions like Heart failure.
Interactions
Amrinone (Lactate) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCilostazolephosphoiestase inhitorsImmediate These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Decreased potassium serum concentrationsIncreased hepatic enzyme concentrations.
Risks
Drug should not be given to Cardiac / Hypertensive Patients.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Inj Store at room temperature. Protect from Sunlight.
Warnings
It should be used cautiously in severe obstructive aortic or pulmonary valvular disease or in hypertrophic cardiomyopathy. Blood pressure and heart rate should be monitored during parentral administration. The fluid and electrolyte balnace should be maintained. Platelet counts and liver function should also be monitored.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.